José Mayordomo

Medicine · Health Sciences

57h-index18.8kcitations231works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(61), HER2/EGFR in Cancer Research(44), Cancer Treatment and Pharmacology(42), Breast Cancer Treatment Studies(35), Genetic Associations and Epidemiology(24)

Publications231 total

Supplementary Table S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Fig. S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Table S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Fig. S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Fig. S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Fig. S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Table S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Table S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Table S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Fig. S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Table S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Fig. S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Fig. S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Table S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Data from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Fig. S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Table S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024Open Access
Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Lambertus A. Kiemeney(29), Kāri Stefánsson(27), Patrick Sulem(26), Þórunn Rafnar(26), Simon Stacey(23), Katja K.H. Aben(23), Daníel F. Guðbjartsson(23), Unnur Þorsteinsdóttir(23), Jūlı́us Guðmundsson(22), Augustine Kong(21), Jeffrey R. Gulcher(18), Ásgeir Sigurðsson(18), Guðmar Þorleifsson(15), Kristleifur Kristjánsson(15), Margret Jakobsdottir(13), Berta Sáez(13), Kristrún R. Benediktsdóttir(13), Gísli Másson(12), Eiríkur Jónsson(11), Sigurjón A. Guðjónsson(11)